Skip to main content
. 2020 Nov 12;10:19626. doi: 10.1038/s41598-020-76577-2

Table 2.

Clinicopathologic feature of breast cancer patients [n(%)].

Variable Total
n = 206
Control (non metastasis)
n = 103
Metastasis
n = 103
P-value
Age
< 50 98 47 (45.6) 51 (49.5) 0.577
≥ 50 108 56 (54.4) 52 (50.5)
ER
Negative 79 33 (32.0) 46 (44.7) 0.032*
Positive 127 70 (68.0) 57 (55.3)
PR
Negative 108 46 (44.7) 62 (60.2) 0.714*
Positive 98 57 (55.3) 41 (39.8)
HER2
−/+ 138 68(66.0) 70(68.0) 0.001*
+++ 68 35 (34.0) 33 (32.0)
E-Cad
Negative 24 14 (13.6) 10 (9.7) < 0.001*
Positive 182 89 (86.4) 93 (90.3)
P53
Negative 107 58 (56.3) 49 (47.6) 0.757*
Positive 99 45 (43.7) 54 (52.4)
Ki67
< 20 54 31 (30.1) 23 (22.3) < 0.001*
≥ 20 152 72 (69.9) 80 (77.7)
Molecular subtypes
Luminal A 36 22 (21.4) 14 (13.6) 0.064
Luminal B 55 27 (26.2) 28 (27.2)
Luminal HER2 45 25 (24.3) 20 (19.4)
HER2-enriched 23 10 (9.7) 13 (12.6)
Basal-like 47 19 (18.4) 28 (27.2)
Lymph node metastasis
0 71 49 (47.6) 22 (21.4) 0.000
1 ~ 3 43 27 (26.2) 16 (15.5)
4 ~ 9 38 12 (11.7) 26 (25.2)
≥ 10 54 15 (14.6) 39 (37.9)
Pathological type
Carcinoma in situ 11 7 (6.8) 4 (3.9) 0.405
Non-specific invasive carcinoma 193 95 (92.2) 98 (95.1)
Invasive special type carcinoma 2 1 (1.0) 1 (1.0)
Tumor size
< 2 cm 60 33 (32.0) 27 (26.2) 0.819
≥ 2 cm and ≤ 5 cm 120 55 (53.4) 65 (63.1)
> 5 cm 26 15 (14.6) 11 (10.7)
WHO grade
I 9 8 (7.8) 1 (1.0) 0.465
II 128 60 (58.3) 68 (66.0)
III 69 35 (34.0) 34 (33.0)

*P values were calculated by pairwise comparisons from McNemar’s test. P values were calculated by comparisons of groups from Wilcoxon signed-rank test.